Applying Clinical Trial Data to Real World Patients in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians interpret clinical trial results in the context of real world patient populations with metastatic castration sensitive prostate cancer (mCSPC). Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram highlight that patients enrolled in randomized clinical trials are often highly selected and may not fully reflect the complexity seen in routine practice. Many real world patients are older, have multiple comorbidities, and take several concomitant medications, which can influence treatment tolerance and outcomes. The panel explains that while clinical trials provide essential evidence supporting treatment intensification strategies, physicians must carefully consider how applicable those findings are to individual patients. The discussion emphasizes the importance of clinical judgment when translating trial data into practice. This segment illustrates how clinicians integrate high quality clinical trial evidence with real world patient characteristics to guide treatment decisions in metastatic castration sensitive prostate cancer.